| abstract |
Disclosed are novel amines and their pharmaceutically acceptable salts of the following Formulas 1D and 1E, which are useful for the treatment of epilepsy, syncope, hypomotility, cranial diseases, neurodegenerative diseases, depression, anxiety, phobias, Inflammatory diseases and gastrointestinal diseases, in particular IBS.n n n ≪ Formula 1D >n n n n n n n n ≪ EMI ID =n n n n n n n n Wherein,n n n n is an integer of 0 to 2,n n n R is sulfonamide, amide, phosphonic acid, heterocycle, sulfonic acid or hydroxamic acid,n n n X is -O-, -S-, -S (O) -, -S (O) 2 - or NR '1 (wherein, R' 1 is hydrogen, the carbon atom number of 1 to 6 linear or branched alkyl or benzyl), -C (O) R ' 2 ( wherein, R' 2 is a carbon atom number of 1 to 6 linear or branched alkyl, benzyl or phenyl), or -CO 2 R '3 (wherein, R' 3 Is a straight or branched chain alkyl having 1 to 6 carbon atoms or a phenyl or benzyl group unsubstituted or substituted with one to three substituents selected from halogen, trifluoromethyl and nitro. |